Trial reportRespiratory research2019
Association of platelet count with all-cause mortality and risk of cardiovascular and respiratory morbidity in stable COPD.
Trial report in Respiratory research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01313676 (A Clinical Outcomes Study to Compare the Effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg With Placebo on Survival in Subjects With Moderate Chronic Obstructive Pulmonary Disease), which is not on this map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Clinical Outcomes Study to Compare the Effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg With Placebo on Survival in Subjects With Moderate Chronic Obstructive Pulmonary Disease (COPD) and a History of or at Increased Risk for Cardiovascular Disease
Who cites it
28 citing papers in PubMed, 35 citations in OpenAlex.
- The elevated CXCL5 levels in circulation are associated with lung function decline in COPD patients and cigarette smoking-induced mouse model of COPD.Annals of medicineTrial
- Association between platelet count and 30-day mortality in community-acquired pneumonia patients receiving systemic glucocorticoids therapy.Scientific reports · 2026Article
- Association of thrombocytopenia with deep vein thrombosis in patients with acute exacerbations of chronic obstructive pulmonary disease: A retrospective study.Experimental and therapeutic medicine · 2026Article
- Platelet count has a U-shaped association with all-cause mortality in COPD patients.Scientific reports · 2026Article
- Web-based cardiovascular disease risk prediction using machine learning.Frontiers in artificial intelligence · 2026Article
- Association of Lung Quantitative CT Scan Textures With Systemic Inflammation and Mortality in COPD.Chest · 2025Article
- Development and validation of a machine learning-based model to predict the risk of hospitalization death in hospitalized patients with AECOPD.Scientific reports · 2025Article
- Article
- Association Between Platelet Indices and Risk of Chronic Obstructive Pulmonary Disease: A Bidirectional Mendelian Randomization Study.International journal of chronic obstructive pulmonary disease · 2025Article
- Association between systemic immune-inflammation index and mortality in critically ill patients with chronic obstructive pulmonary disease: insights from the MIMIC-IV database.Frontiers in medicine · 2025Article
- Inflammatory markers as predictors of in-hospital mortality in acute exacerbation of chronic obstructive pulmonary disease (AECOPD) patients with acute respiratory failure: insights from the MIMIC-IV database.Journal of thoracic disease · 2024Article
- Platelet count has a U-shaped association with mortality in hemodialysis patients.Scientific reports · 2024Article
- Development and validation of a mortality risk prediction model for chronic obstructive pulmonary disease: a cross-sectional study using probabilistic graphical modelling.EClinicalMedicine · 2024Article
- Prognostic Significance of Thrombocytopenia and Mean Platelet Volume in COPD Patients with Acute Exacerbations in ICU Settings.Medical science monitor : international medical journal of experimental and clinical research · 2024Article
- Key role of activated platelets in the enhanced adhesion of circulating leucocyte-platelet aggregates to the dysfunctional endothelium in early-stage COPD.Frontiers in immunology · 2024Article
- A Low Eosinophil to Platelet Ratio as a Worse Prognostic Index for Emergency Department Attendance in Acute Exacerbation of COPD.International journal of chronic obstructive pulmonary disease · 2024Article
- Red blood cell distribution width/platelet ratio on admission as a predictor for in-hospital mortality in patients with acute myocardial infarction: a retrospective analysis from MIMIC-IV Database.BMC anesthesiology · 2023Article
- A Prediction Model for In-Hospital Mortality of Acute Exacerbations of Chronic Obstructive Pulmonary Disease Patients Based on Red Cell Distribution Width-to-Platelet Ratio.International journal of chronic obstructive pulmonary disease · 2023Article
- Article
- Thrombocytopenia predicts mortality in Chinese hemodialysis patients- an analysis of the China DOPPS.BMC nephrology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
backgroundPlatelet count is a prognostic indicator in the general population and elderly. Thrombocytosis during acute exacerbation of COPD (AECOPD) has been associated with mortality; however, the relationship between platelet count and mortality in stable COPD is unknown.
methodsWe performed post hoc secondary analysis on a subsample of 1797 patients in the Study to Understand Mortality and Morbidity in COPD (SUMMIT) who had blood samples drawn at baseline. Participants were current or former smokers, 40-80 years old with moderate COPD and history or increased risk of cardiovascular (CV) disease. The primary outcome was on and post-treatment all-cause mortality. Secondary outcomes included first-on-treatment moderate/severe AECOPD and on-treatment CV composite event (CV death, myocardial infarction, stroke, unstable angina and transient ischemic attack). Multivariable Cox proportional hazards models were used to investigate study endpoint associations with platelet count quintile grouping, continuous platelet count utilizing two-term fractional polynomials, and categories of low, normal and high platelet count (< 150, ≥150 to < 300, ≥300 × 10
resultsPatients were followed for 2.3 ± 0.9 years for vital status and 1.6 ± 1.1 years for morbidity endpoints during which 105 (5.8%) died, 651 (36.2%) experienced AECOPD (159 with severe AECOPD) and 86 (4.8%) experienced a CV event. A U-shaped association between platelet count and all-cause mortality was observed. Compared to the third quintile group (Q3) of platelet count, risk of death was increased in the lowest quintile group (Q1; hazard ratio [HR]: 1.73; 95% confidence interval [CI]: 0.93-3.23) and highest quintile group (Q5; HR: 1.66; 95%CI: 0.89-3.10), though point estimates were imprecise. Using clinical cutoffs, compared with normal platelet counts (≥150 to < 300 × 10
conclusionsIn stable COPD platelet count demonstrated a U-shaped association with increased risk of 3-year all-cause mortality, though a platelet count level above or below which risk of mortality was increased could not be definitively identified.
trial registrationClinicalTrials.gov NCT01313676 .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.